The multicenter trial will examine the effectiveness of CSC's patient specific cancer immunotherapy in patients with recurrent stage III or stage IV metastatic melanoma.
http://eon.businesswire.com/news/eon/20130726005152/en/California-Stem-Cell-Submits-FDA-Phase-III
http://eon.businesswire.com/news/eon/20130726005152/en/California-Stem-Cell-Submits-FDA-Phase-III
No comments:
Post a Comment